Could an Anti-Inflammatory pill help control diabetes?
NCT ID NCT06047262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests dapansutrile, an oral drug that reduces inflammation, in 300 adults with type 2 diabetes. The goal is to see if it improves blood sugar control and lowers the risk of diabetes-related complications. Participants are randomly assigned to receive either the drug or a placebo for comparison.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapansutrile (an oral anti-inflammatory drug)
What this could lead to
If successful, this could offer a new way to manage type 2 diabetes by reducing inflammation, potentially lowering blood sugar and risk of complications.
What could go wrong
This is an early Phase 2 trial with 300 people, so results are not yet proven. The drug may not improve blood sugar control or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Liege
RECRUITINGLiège, 4000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Deutsches Zentrum für Diabetesforschung Düsseldorf
RECRUITINGDüsseldorf, Nordrhein-Westphalen, 40225, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Bichat
RECRUITINGParis, Île-de-France Region, 75018, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Lariboisiere
RECRUITINGParis, Île-de-France Region, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kantonsspital Olten
RECRUITINGOlten, Canton of Solothurn, 4600, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Basel
TERMINATEDBasel, Basel, 4031, Switzerland